Representing Fearless andUndaunted Innovators.
The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Firm Advises Underwriters on Legend Biotech’s Public Offering
On June 17, 2026, Legend Biotech Corporation, a global leader in cell therapy, announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs), each representing two ordinary shares of the company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, were approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. Wilson Sonsini Goodrich & Rosati advised the underwriters on the transaction.
Client Highlights
Wilson Sonsini Advises Assort Health on $120 Million Series C
On June 24, 2026, Assort Health, the most widely used AI agents platform for the patient journey, announced a $120 million Series C led by Menlo Ventures at a valuation of $1.2 billion. Assort has now raised more than $222 million to become the standard for healthcare organizations wanting to transform the patient journey with AI. Wilson Sonsini Goodrich & Rosati advised Assort on the transaction.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
In addition to Menlo Ventures, investors participating in the Series C financing include Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital.
What began as the first voice AI agent to schedule a specialty appointment is now a platform spanning scheduling, intake forms, referrals, document processing, medication refills, real time eligibility, lab requests, and payments. That expansion has been powered by more than 190 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.
The Wilson Sonsini team that advised Assort on the financing included Lang Liu, Alex Youssef, Madisyn Klein, and Nara Jo.
For more information, please see Assort’s blog post.
Client Highlights
Firm Advises QCi on Acquisition of NHanced
On June 22, 2026, Quantum Computing Inc. (QCi), an innovative, quantum optics and integrated photonics technology company, announced the completion of acquiring NHanced Semiconductors for a combination of cash and QCi stock valued at $73.1 million, subject to customary adjustments, and up to an additional $72.0 million if certain performance targets are achieved. Wilson Sonsini Goodrich & Rosati advised QCi on the transaction.
Client Highlights
Firm Advises Denali Therapeutics on Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
On June 18, 2026, Denali Therapeutics, a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform, announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. Wilson Sonsini Goodrich & Rosati advised Denali on the transaction.
Client Highlights
Wilson Sonsini Advises SandboxAQ on Agreement with the U.S. Department of Commerce for $500 Million CHIPS R&D Award
On June 17, 2026, SandboxAQ announced a definitive agreement with the U.S. Department of Commerce's CHIPS Research and Development Office for a $500 million award to address one of the most urgent challenges in American manufacturing: the foreign control of critical materials and chemistries that are essential to semiconductor manufacturing. Wilson Sonsini Goodrich & Rosati advised SandboxAQ on the transaction.
Client Highlights
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.